Results 71 to 80 of about 5,935 (185)

Early and long-term outcome of elective stenting of the infarct-related artery in patients with viability in the infarct-area: Rationale and design of the Viability-guided Angioplasty after acute Myocardial Infarction-trial (The VIAMI-trial)

Current Controlled Trials in Cardiovascular Medicine, 2004
Background Although percutaneous coronary intervention (PCI) is becoming the standard therapy in ST-segment elevation myocardial infarction (STEMI), to date most patients, even in developed countries, are reperfused with intravenous thrombolysis or do ...
Visser Cees A, Bronzwaer Jean GF, Kamp Otto, Veen Gerrit, van Loon Ramon B, Visser Frans C   +5 more
doaj   +1 more source

Investigation of interaction of human platelet membrane components with anticoagulant drugs Abciximab and Eptifibatide

Folia Histochemica et Cytobiologica, 2010
Abciximab (Abci) and eptifibatide (Epti) are antiaggregate drugs which may reduce thrombotic complications inacute coronary syndromes. The aim of this work was the investigation of the interaction between the phospholipid-GPIIb/IIIa glycoprotein complex ...
Ewa Gorodkiewicz, Anna Sankiewicz, Zbigniew A. Figaszewski   +2 more
doaj  

On the use of abciximab in percutaneous coronary intervention

, 2011
Introduction: The present thesis ´On the use of abciximab in percutaneous coronary intervention´ is based on 6 papers concerning the glycoprotein IIb/IIIa inhibitor, abciximab. The thesis is divided into 2 sections.
Iversen, Allan
core   +1 more source

Abciximab for thrombolysis during intracranial aneurysm coiling [PDF]

, 2018
Introduction: Thrombotic events are a common and severe complication of endovascular aneurysm treatment with significant impact on patients' outcome.
Lalloo, Shivendra, Kuker, Wilhem, Molyneux, Andrew, Gralla, Jan, Corkill, Rufus, Byrne, James, Rennie, Adam   +6 more
core  

Antiplatelet medications in acute coronary syndromes and percutaneous coronary interventions: focus on tirofiban

Кардиоваскулярная терапия и профилактика, 2008
The review presents literature data on the key role of platelet aggregation (PA) for intracoronary thrombogenesis in various acute coronary syndromes (ACS) and percutaneous coronary interventions (PCI).
T. A. Batyraliev, D. V. Preobrazhensky, D. V. Fetzer, B. A. Sidorenko, S. A. Pataraya   +4 more
doaj  

High bolus tirofiban vs abciximab in acute STEMI patients undergoing primary PCI - The tamip study

Heart Views, 2012
Background: Primary percutaneous coronary intervention (PCI) has been shown to be an effective therapy for patients with acute myocardial infarction (MI). Glycoprotein (GP) IIb/IIIa receptor blockers reduce thrombotic complications in patients undergoing
Mohammed A Balghith
doaj   +1 more source

Intracranial bleeding mimicking an extensive acute myocardial infarction with reversible apical ballooning and systolic left ventricular dysfunction. A case report

Monaldi Archives for Chest Disease, 2016
A novel syndrome with transient asynergy of the apical segments of the left ventricle, also known as tako-tsubo cardiomyopathy, has been recently described and presents characteristics and effects similar to acute myocardial infarction.
Antonio D’Aloia, Enrico Vizzardi, Pompilio Faggiano, Claudia Fiorina, Livio Dei Cas   +4 more
doaj   +1 more source

Terapia con anticuerpos monoclonales en Cardiología y Medicina Interna

Revista Colombiana de Cardiología, 2016
La terapia biológica basada en anticuerpos monoclonales, constituyen una nueva herramienta terapéutica, que de la mano del desarrollo de la biología molecular permiten intervenir puntos claves en la etiopatogenia de la enfermedad, permitiendo una terapia
Christian David Adams-Sánchez, Gabriel Jaime Tobón-García   +1 more
doaj   +1 more source

In vitro measurement of platelet glycoprotein IIb/IIIa receptor blockade by abciximab: interindividual variation and increased platelet secretion

Haematologica, 2001
BACKGROUND AND OBJECTIVES: Inhibition of soluble fibrinogen binding to activated platelets represents the target of pharmacologic approach with antagonists of the glycoprotein IIb/IIIa (GPIIb/IIIa) complex.
F Rossi, E Rossi, FI Pareti, S Colli, E Tremoli, L Gallo   +5 more
doaj  

An Additional Mechanism of Action of Abciximab: Dispersal of Newly Formed Platelet Aggregates

, 2002
SummaryThe ability of abciximab to prevent fibrinogen binding to activated platelets indicates it may also promote dissolution of platelet-rich thrombi. The present study examined the capacity of abciximab to reverse platelet aggregation in vitro.
Andrew Frelinger, Joseph Jakubowski, Robert Jordan, Mary Mascelli, Peter Marchese, Stanley Marciniak, Mark Furman, Alan Michelson   +7 more
core   +1 more source